Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Naltrexone/Bupropion in Healthy Subjects
NCT02735603Phase 1Completed
- Sponsor
- Orexigen Therapeutics
- Start
- Apr 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naltrexone + bupropion in obesity (6 arms), sponsored by Orexigen Therapeutics. Primary endpoint: QT interval with Fridericia correction method at Day 11. Started Apr 2016; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02735603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735603.